CY1122072T1 - Μη-ανταγωνιστικα αντισωματα κατευθυνομενα εναντι της αλφα αλυσου του εξωκυτταρικου πεδιου υποδοχεα il7 και χρηση αυτων σε θεραπεια καρκινου - Google Patents
Μη-ανταγωνιστικα αντισωματα κατευθυνομενα εναντι της αλφα αλυσου του εξωκυτταρικου πεδιου υποδοχεα il7 και χρηση αυτων σε θεραπεια καρκινουInfo
- Publication number
- CY1122072T1 CY1122072T1 CY20191100905T CY191100905T CY1122072T1 CY 1122072 T1 CY1122072 T1 CY 1122072T1 CY 20191100905 T CY20191100905 T CY 20191100905T CY 191100905 T CY191100905 T CY 191100905T CY 1122072 T1 CY1122072 T1 CY 1122072T1
- Authority
- CY
- Cyprus
- Prior art keywords
- receptor
- extracellular domain
- alpha chain
- directed against
- antibodies directed
- Prior art date
Links
- 108010038498 Interleukin-7 Receptors Proteins 0.000 title abstract 3
- 102000010782 Interleukin-7 Receptors Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000036963 noncompetitive effect Effects 0.000 title 1
- 102000000704 Interleukin-7 Human genes 0.000 abstract 3
- 108010002586 Interleukin-7 Proteins 0.000 abstract 3
- 229940100994 interleukin-7 Drugs 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 abstract 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000052622 human IL7 Human genes 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η περιγραφή αφορά εξανθρωπισμένα αντισώματα που κατευθύνονται έναντι του εξωκυτταρικού πεδίου της άλφα αλύσου του υποδοχέα για ιντερλευκίνη-7 (IL-7), ειδικώς έναντι του υποδοχέα για ανθρώπινη IL-7, εκφρασμένη επί ανθρώπινων κυττάρων (επίσης οριζόμενος ανθρώπινος ΙL-7Rάλφα ή IL- 7Ra ή CD127) και τα οποία δεν αλληλεπιδρούν με τα μονοπάτια σηματοδότησης IL-7 ή TSLP. Τα περιγραφόμενα αντισώματα δεν έχουν ανταγωνιστικό αποτέλεσμα επί του υποδοχέα IL-7, αλλά μπορεί εισέτι να παρουσιάζουν κυτταροτοξική δραστικότητα έναντι CD127 θετικών κυττάρων. Σε μια ιδιαίτερη πραγματοποίηση, το αντίσωμα δεν έχει αποτέλεσμα αγωνιστή επί του υποδοχέα IL-7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301271P | 2016-02-29 | 2016-02-29 | |
| PCT/IB2017/000293 WO2017149394A1 (en) | 2016-02-29 | 2017-02-28 | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122072T1 true CY1122072T1 (el) | 2020-11-25 |
Family
ID=58530580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100905T CY1122072T1 (el) | 2016-02-29 | 2019-08-23 | Μη-ανταγωνιστικα αντισωματα κατευθυνομενα εναντι της αλφα αλυσου του εξωκυτταρικου πεδιου υποδοχεα il7 και χρηση αυτων σε θεραπεια καρκινου |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11230602B2 (el) |
| EP (1) | EP3423496B1 (el) |
| JP (1) | JP7053479B2 (el) |
| KR (1) | KR20180118746A (el) |
| CN (1) | CN109195987B (el) |
| AU (1) | AU2017225495B2 (el) |
| BR (1) | BR112018067479A2 (el) |
| CA (1) | CA3014313A1 (el) |
| CY (1) | CY1122072T1 (el) |
| DK (1) | DK3423496T3 (el) |
| ES (1) | ES2737307T3 (el) |
| HR (1) | HRP20191445T1 (el) |
| HU (1) | HUE045183T2 (el) |
| IL (1) | IL261330B2 (el) |
| LT (1) | LT3423496T (el) |
| MA (1) | MA43767B1 (el) |
| MD (1) | MD3423496T2 (el) |
| ME (1) | ME03446B (el) |
| PL (1) | PL3423496T3 (el) |
| PT (1) | PT3423496T (el) |
| RS (1) | RS59223B1 (el) |
| SI (1) | SI3423496T1 (el) |
| WO (1) | WO2017149394A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| US20200362300A1 (en) * | 2017-08-29 | 2020-11-19 | Ose Immunotherapeutics | Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy |
| US11970532B2 (en) * | 2018-05-10 | 2024-04-30 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
| KR20220100567A (ko) * | 2019-06-28 | 2022-07-15 | 더 유니버시티 오브 멜버른 | 감마 델타 t 세포의 억제 또는 활성화 방법 |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| CA3181394A1 (en) * | 2020-04-27 | 2021-11-04 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting cd127 and use thereof |
| CA3179308A1 (en) * | 2020-05-18 | 2021-11-25 | Hassan JUMAA-WEINACHT | Composition for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP3431585A1 (en) | 2006-05-31 | 2019-01-23 | The Regents of The University of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| AU2011209713B2 (en) * | 2010-01-28 | 2014-04-03 | Glaxo Group Limited | CD127 binding proteins |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| US20150297310A1 (en) | 2014-04-17 | 2015-10-22 | Georgia Regents Research Institute, Inc. | Methods for selecting a treatment for cancer |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
-
2017
- 2017-02-28 MA MA43767A patent/MA43767B1/fr unknown
- 2017-02-28 WO PCT/IB2017/000293 patent/WO2017149394A1/en active Application Filing
- 2017-02-28 SI SI201730078T patent/SI3423496T1/sl unknown
- 2017-02-28 DK DK17716593.3T patent/DK3423496T3/da active
- 2017-02-28 HU HUE17716593A patent/HUE045183T2/hu unknown
- 2017-02-28 PT PT17716593T patent/PT3423496T/pt unknown
- 2017-02-28 US US16/080,572 patent/US11230602B2/en active Active
- 2017-02-28 CA CA3014313A patent/CA3014313A1/en active Pending
- 2017-02-28 ES ES17716593T patent/ES2737307T3/es active Active
- 2017-02-28 PL PL17716593T patent/PL3423496T3/pl unknown
- 2017-02-28 BR BR112018067479A patent/BR112018067479A2/pt unknown
- 2017-02-28 IL IL261330A patent/IL261330B2/en unknown
- 2017-02-28 RS RSP20190987 patent/RS59223B1/sr unknown
- 2017-02-28 KR KR1020187028377A patent/KR20180118746A/ko not_active Application Discontinuation
- 2017-02-28 AU AU2017225495A patent/AU2017225495B2/en active Active
- 2017-02-28 ME MEP-2019-215A patent/ME03446B/me unknown
- 2017-02-28 MD MDE20190066T patent/MD3423496T2/ro not_active IP Right Cessation
- 2017-02-28 LT LTEP17716593.3T patent/LT3423496T/lt unknown
- 2017-02-28 JP JP2018545380A patent/JP7053479B2/ja active Active
- 2017-02-28 EP EP17716593.3A patent/EP3423496B1/en active Active
- 2017-02-28 CN CN201780014099.2A patent/CN109195987B/zh active Active
-
2019
- 2019-08-09 HR HRP20191445 patent/HRP20191445T1/hr unknown
- 2019-08-23 CY CY20191100905T patent/CY1122072T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL261330A (en) | 2018-10-31 |
| AU2017225495B2 (en) | 2024-05-09 |
| ME03446B (me) | 2020-01-20 |
| US20200308288A1 (en) | 2020-10-01 |
| EP3423496A1 (en) | 2019-01-09 |
| JP2019515648A (ja) | 2019-06-13 |
| AU2017225495A1 (en) | 2018-08-23 |
| MD3423496T2 (ro) | 2020-01-31 |
| KR20180118746A (ko) | 2018-10-31 |
| PT3423496T (pt) | 2019-09-05 |
| MA43767B1 (fr) | 2019-08-30 |
| CN109195987A (zh) | 2019-01-11 |
| RS59223B1 (sr) | 2019-10-31 |
| DK3423496T3 (da) | 2019-08-19 |
| LT3423496T (lt) | 2019-09-25 |
| CA3014313A1 (en) | 2017-09-08 |
| MA43767A (fr) | 2019-01-09 |
| HRP20191445T1 (hr) | 2019-11-15 |
| IL261330B2 (en) | 2023-03-01 |
| HUE045183T2 (hu) | 2019-12-30 |
| JP7053479B2 (ja) | 2022-04-12 |
| US11230602B2 (en) | 2022-01-25 |
| EP3423496B1 (en) | 2019-07-03 |
| CN109195987B (zh) | 2022-05-27 |
| WO2017149394A1 (en) | 2017-09-08 |
| PL3423496T3 (pl) | 2020-01-31 |
| IL261330B (en) | 2022-11-01 |
| BR112018067479A2 (pt) | 2019-01-15 |
| ES2737307T3 (es) | 2020-01-13 |
| SI3423496T1 (sl) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122072T1 (el) | Μη-ανταγωνιστικα αντισωματα κατευθυνομενα εναντι της αλφα αλυσου του εξωκυτταρικου πεδιου υποδοχεα il7 και χρηση αυτων σε θεραπεια καρκινου | |
| CY1119510T1 (el) | Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης | |
| CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
| CO2020000438A2 (es) | Anticuerpos anti-ctla-4 y sus usos | |
| CY1123972T1 (el) | Θεραπεια συνδυασμου για καρκινο | |
| CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
| CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
| CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
| AR114283A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| UY36692A (es) | Anticuerpos anti-cd40 y usos de los mismos | |
| EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| MX2018000278A (es) | Terapia de receptores quimericos de puntos de control inmunitarios. | |
| EA202090204A1 (ru) | Анти-cd137 антитела | |
| CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
| CR20160314A (es) | Anticuerpos anti-cd3 y metodos de uso | |
| CR20160576A (es) | Anticuerpos dirigidos contra cd127 | |
| CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| CL2020001264A1 (es) | Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide. | |
| EA201992248A1 (ru) | АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |